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Abstract: Tuberculosis, one of the oldest diseases affecting human beings, is still considered as a world public health 
problem by the World Health Organization. Therefore, there is a need for new and more powerful analytical methods for 
early illness diagnosis. With this idea in mind, the development of a High Fundamental Frequency (HFF) piezoelectric 
immunosensor for the sensitive detection of tuberculosis was undertaken. A 38 kDa protein secreted by Mycobacterium 
tuberculosis was first selected as the target biomarker. Then, specific monoclonal antibodies (MAbs) were obtained. Myc-31 
MAb, which showed the highest affinity to the analyte, was employed to set up a reference enzyme-linked immunosorbent 
assay (ELISA) with a limit of detection of 14 ng mL-1 of 38 kDa antigen. 
For the development of the HFF piezoelectric immunosensor, 100 MHz quartz crystals were used as transducer elements. The 
gold electrode surface was functionalized by covalent immobilization of the target biomarker through mixed self-assembled 
monolayers (mSAM) of carboxylic alkane thiols. A competitive immunoassay based on Myc-31 MAb was integrated with 
the transducer as sensing bio-recognition event. Reliable assay signals were obtained using low concentrations of antigen for 
functionalization and MAb for the competitive immunoassay. Under optimized conditions, the HFF immunosensor 
calibration curve for 38 kDa determination showed a limit of detection as low as 11 ng mL-1 of the biomarker. The high 
detectability attained by this immunosensor, in the picomolar range, makes it a promising tool for the easy, direct and 
sensitive detection of the tuberculosis biomarker in biological fluids such as sputum. 
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1. INTRODUCTION 
     Tuberculosis (TB) is a public health problem that affects 
millions of people around the world, and it is the second 
cause of death due to infectious illness after the Human 
Immunodeficiency Virus. According to reports by the World 
Health Organization, more than nine million new cases of 
TB are reported every year, resulting in the deaths of 
approximately two million people. Currently, one of the 
main challenges in controlling TB is the implementation of 
alternative diagnosis methods for early detection [1],[2]. 
     Many tests developed for TB diagnosis are based on 
molecular biology techniques, which give results in a few 
hours. However, their routine use in vulnerable endemic 
areas is reduced by the costs of this technology and the high 
level of technical training needed for health professionals. 
Therefore, in many affected areas the strategy for controlling 
the illness is still based on the sputum coloration and culture. 
The main disadvantage of these traditional methods is the 
long time required before results are available, which affects 
the opportune starting of treatment, thereby increasing the 
rates of the illness spreading [3]. 
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     As a response to these limitations in current detection 
techniques, alternative detection methods based on 
biosensors have been developed [4]-[10]. As known, 
biosensors are analytical devices that integrate a biological 
component (the bio-receptor) with an electronic or 
optoelectronic transducer to detect and quantify the presence 
of target analytes in complex samples. In a very recent report 
[11], the state of the art and the main analytical performance, 
advantages and drawbacks of different biosensor approaches 
to the detection of tuberculosis are exhaustively reviewed. 
To date, electrochemical, optical, mechanical (including 
piezoelectric) and magnetic biosensors have been or are 
being developed, with different sensitivities. The reported 
limits of detection are highly variable among devices, 
ranging from 20 to 107 colony forming units (CFU) per mL 
for Mycobacterium tuberculosis (Mbt) cells or from 0.1 to 30 
ng mL-1 for different biomarker antigens.     
     Biosensors using immunoreactive bio-receptors and 
piezoelectric crystals working in the Quartz Crystal 
Microbalances (QCM) mode as transducers are known as 
piezoelectric immunosensors [12]. A piezoelectric crystal 
acting as a QCM allows the  measurement of changes in the 
surface mass density that occur in an infinitesimally thin 
layer in contact with the crystal, considered to be rigid. 
Changes in this thin layer modify the piezoelectric 
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electroacoustic properties of the sensor. Two methods are 
used in biosensors to obtain mass variation, based on the 
measurement of one of the sensor electric variables: 
resonance frequency and phase. 
     The first method is based on the continuous measurement 
of the crystal resonance frequency (f). The resonance 
frequency variation is related to variations in the surface 
mass density deposited on the crystal surface according to 
Sauerbrey’s equation [13]: 
Δf  =   ̶  (2f0
2/Zcq)ρs  =   ̶  CSB ρs  (Eq. 1) 
Where:  
f0: Resonance frequency in vacuum. 
Zcq: Acoustic impedance characteristic of quartz. 
ρs: Surface mass density (density of the thin layer deposited 
on the crystal). 
CSB: Sauerbrey’s coefficient. 
     The second method is based on interrogating the 
piezoelectric crystal with a signal at a constant frequency 
near the crystal resonance frequency and measuring the 
signal phase (φ). The changes produced in the signal phase 
are related to the mass variations on the crystal surface 
according to the phase equation [14]: 
Δ φ =   ̶  (ΔmS /mL)   (Eq. 2) 
Where: 
ms: Surface mass density in contact with the crystal 
mL: Effect of the liquid displaced by the crystal 
An infinitesimally thin rigid layer can be generated on 
the surface of a quartz crystal gold electrode by covalent 
immobilizing through a self-assembled monolayer (SAM) of 
an immunoreagent (an antigen or an antibody). When the 
functionalized piezoelectric sensor is put in contact with a 
complex sample, the antigen-antibody interactions that occur 
between the immunoreagent immobilized on the crystal and 
those in the sample modify the electric properties of the 
QCM. This allows to establish a clear relationship between 
the variations of analyte concentration in the sample and 
mass-related signal changes in the sensor. 
Piezoelectric biosensors have been reported for detection 
or diagnosis of diseases such as hepatitis C [15], hepatitis B 
[16], thalassemia [17], malaria [18] and human papilloma 
virus [19]. Although QCM offer many benefits, including 
low cost, ease of use, real-time analysis and direct detection 
capability without the need of labelling, the development of 
piezoelectric biosensors applied to the diagnosis has been 
seriously affected by the low sensitivity offered by the usual 
low-frequency (below 50 MHz) QCM devices. Recently, 
advances in piezoelectric technology led to the development 
of high fundamental frequency microbalances (HFF-QCM) 
that allow for two orders of magnitude increased sensitivity 
[20], which could be useful for the detection of tuberculosis 
biomarkers. This way, HFF-QCM devices could provide 
effective, fast and accessible alternative methods for TB 
detection, meeting analytical performance requirements such 
as high sensitivity, rapidity in providing results, ease of use 
and even portability [21]. 
Some piezoelectric immunosensors have been reported to 
be able to detect TB [22],[23]. These biosensors are based on 
low-frequency QCM sensors and on direct immunoassays 
with immobilized antibodies for the detection of Mbt CFUs 
or biomarkers.  With this frequency and assay configuration, 
the biosensor sensitivity and the biochemical stability of the 
antibodies were too poor, which seriously affects the 
usefulness of the biological interface and increases the cost 
of immobilization. 
In the present paper, the development of an HFF-QCM 
piezoelectric immunosensor for highly sensitive detection of 
a TB biomarker is described. To this purpose, the 38 kDa 
antigen from Mbt was first selected as the disease biomarker. 
This lipo-glyco-protein is one of the immunodominant 
antigens in the microorganism and is considered as a good 
indicator of both the progress of the illness and the 
effectiveness of the treatment [24],[25]. Consequently, the 
38 kDa antigen is among the most widely used biomarkers in 
the development of TB diagnostic methods based on 
immunoassays [26]-[28]. 
Monoclonal antibodies (Mab) specific to the target 
biomarker were obtained. The highest-affinity one was used 
as the primary immunoreagent for the development of a 
competitive enzyme-linked immunosorbent assay (ELISA) 
for 38 kDa quantification. This ELISA was used as a 
previous diagnostic test and reference assay for the 
biosensor. Finally, the HFF piezoelectric immunosensor was 
developed for the detection and quantification of the 38 kDa 
antigen. High frequency (100 MHz) quartz crystals were 
used as biosensor transducers. The crystals were 
functionalized by covalently immobilization of the 38 kDa 
antigen on the surface of the quartz crystal gold electrode 
and a monoclonal antibody-based competitive immunoassay 
was integrated as the sensing specific bio-recognition event 
coupled to the transducer. The analytical performance of the 
developed ELISA and HFF-QCM immunosensor are 
presented and discussed.  
2. MATERIALS AND METHODS 
2.1. Reagents and instruments 
2.1.1. General: 
Bovine serum albumin (BSA) fraction V was purchased 
from Roche Diagnostics (Mannheim, Germany). Tween-20 
was from by Fluka-Aldrich Chemie (Buchs, Switzerland). 
All other chemicals were of analytical grade. Flat bottom 
polystyrene ELISA plates (High Binding Plates) were from 
Costar (Cambridge, MA). 100 MHz HFF-QCM crystals 
were from AWSensors (Valencia, Spain). 
2.1.2. Immunoreagents: 
The selected antigen for mouse immunization was a 
recombinant form of the 38 kDa protein from Mbt. It was 
supplied by MyBioSource (San Diego, CA). The same 
antigen was also used for ELISA plate coating and for 
covalent immobilization onto piezoelectric crystals. 
Peroxidase-labeled rabbit anti-mouse immunoglobulins were 
obtained from Dako (Glostrup, Denmark). 
2.1.3. Reagents for covalent immobilization: 
1-ethyl-3 (-3 dimethyl-amino-propyl) carbodiimide 
hydrochloride (EDC) and N-hydroxysuccinimide (NHS) 
were purchased from Pierce (Rockford, IL); 
mercaptohexadecanoic acid (MHDA) and 11-
mercaptoundecanol (MUD) were supplied by Sigma-Aldrich 
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Chemie  (Steinheim, Germany); ethanolamine blocking 
agent was obtained from Sigma (St. Louis, MO).  
2.1.4. Apparatus 
ELISA plates were washed with a 96PW microplate 
washer from SLT Labinstruments GmbH (Salzburg, 
Austria). Absorbance was read in dual-wavelength mode 
(490650 nm) with an Emax microplate reader from 
Molecular Devices (Sunnyvale, CA). All Immunosensor 
assays were performed in the AWS A20 test platform 
combined with the F20 flow module recently developed by 
AWSensors (www.awsensors.com). 
2.2. Monoclonal antibody production. 
The usual steps involved in hybridoma technology were 
followed: 
2.2.1. Mice immunization: 
Five female BALB/c mice (8-10 weeks old) were 
immunized with the recombinant 38 kDa biomarker from 
Mycobacterium tuberculosis. First dose consisted of 50 μg of 
the antigen intraperitoneally injected as an emulsion of PBS 
(10 mM phosphate buffer, 137 mM NaCl, 2.7 mM KCl, pH 
7.4) and complete Freund's adjuvant. Two and four weeks 
after the initial dose, mice received booster injections with 
the same amount of antigen emulsified in incomplete 
Freund's adjuvant. One week after the last injection, mice 
were tail-bled and sera were tested by ELISA for the 
presence antibodies recognizing the 38 kDa antigen. After a 
resting period of at least three weeks from the last injection 
in adjuvant, mice received a final soluble intraperitoneal 
injection of 50 μg of antigen in PBS, four days prior to 
spleen extraction and cell fusion. 
2.2.2. Cell fusion: 
P3-X63/Ag 8.653 murine myeloma cells (ATCC, 
Rockville, MD) were cultured in high-glucose Dulbecco's 
Modified Eagle's Medium supplemented with 2 mM 
glutamine, 1 mM nonessential amino acids, 25 μg/ml 
gentamicin, and 15% fetal bovine serum (referred to as s-
DMEM, GIBCO, Paisley, UK). Cell fusions were carried out 
essentially as previously described [29]. In summary, mouse 
spleen lymphocytes were fused with myeloma cells at a 5:1 
ratio using Polyethylene Glycol 1500 (Roche Applied 
Science, Mannheim, Germany) as the fusing agent. The 
fused cells were distributed in 96-well culture plates at an 
approximate density of 2 x 105 cells/100 μl of s-DMEM per 
well. Twenty-four h after plating, 100 μl of HAT selection 
medium (s-DMEM supplemented with 100 μM hypoxathine, 
0.4 μM aminopterine, 16 μM thymidine) containing 2% 
Hybridoma Fusion and Cloning Supplement (HFCS, Roche) 
was added to each well. Half the medium of the wells was 
replaced by fresh HAT medium on days 4 and 7 post-fusion. 
Cells were grown in HAT medium for 2 weeks and then 
HAT was substituted by HT medium (HAT medium without 
aminopterine). 
2.2.3. Hybridoma Cloning: 
Eight to ten days after cell fusion, culture supernatants 
were screened by ELISA for the presence of antibodies that 
recognized the 38 kDa target biomarker. Selected 
hybridomas were cloned by the limiting dilution method 
using HT medium. Stable antibody-producing clones were 
expanded and cryopreserved in liquid nitrogen. 
2.2.4. Monoclonal antibody purification: 
MAbs were purified from late stationary phase culture 
supernatants by saline precipitation with 50% saturated 
ammonium sulphate followed by affinity chromatography on 
protein G-Sepharose 4 Fast Flow (GE Healthcare Bio-
Sciences, Uppsala, Sweden). Purified MAbs were finally 
stored at 4 °C as ammonium sulfate precipitates. 
2.3. ELISA development. 
ELISA plates were coated overnight with the 
recombinant 38 kDa antigen in 50 mM carbonate buffer, pH 
9.6. A volume of 100 μL per well was used trough all 
immunoassay steps. All incubations were carried out at room 
temperature. After each incubation, plates were washed four 
times with washing solution (0.15 M NaCl containing 0.05% 
Tween 20). 
2.3.1. Non-competitive ELISA: 
A non-competitive indirect ELISA in the antigen-coated 
format was used to estimate mouse serum antibody titers, for 
the characterization of culture supernatants and antibodies, 
and for checkerboard titration to determine the optimal 
conditions for the quantitative competitive ELISA. Plates 
were coated with the 38 kDa antigen at appropriate 
concentrations. Then, 100 µL of serum, culture supernatant 
or antibody dilution in PBS was added and incubated for 1 h. 
Next, plates were incubated for 1 h with peroxidase-labeled 
rabbit anti-mouse immuno-globulins diluted 1/2000 in PBST 
(PBS containing 0.05% Tween 20). Finally, peroxidase 
activity bound to the wells was determined by adding the 
substrate solution (2 mg/mL OPD and 0.012% H2O2 in 25 
mM citrate, 62 mM sodium phosphate, pH 5.35). After 10 
min, the reaction was stopped with 2.5 M sulphuric acid, and 
the absorbance was read at 490 nm.  
2.3.2. Competitive ELISA for 38 kDa quantification: 
An indirect competitive ELISA was developed for the 
quantification of the target biomarker. The procedure was the 
same as for the non-competitive ELISA except that after 
coating a competition step was introduced by adding 50 
μL/well of 38 kDa antigen standards, followed by 50 μL/well 
of the appropriate concentration of purified Myc-31 
monoclonal antibody. Optimal concentrations of the 38 kDa 
antigen for coating (0.05 µg mL-1) and MAb in solution for 
the competition step (0.05 µg mL-1) were first determined by 
checkerboard titration.  
2.4. HFF-QCM sensor set-up. 
2.4.1. HFF-QCM sensor chip and flow cell assembly: 
Sensors were from AWSensors (Valencia, Spain). They 
were based on square shaped  100 MHz AT-cut, inverted 
mesa crystals, with a total area of 36 mm2 and an etched area 
thickness of around 17 µm. The electrode active surface was 
of 0.785 mm2 for 1.00 mm electrode diameter. 100 MHz 
piezoelectric crystals were assembled on a polyether ether 
ketone (PEEK) support and HFF-QCM chips were 
subsequently mounted into a flow-cell suitable for operation 
at high frequencies as previously described [20]. 
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2.4.2. Measurement platform: 
The flow cell was included in the AWS A20 test 
platform, which was combined with the F20 flow module 
from AWSensors (Fig. 1). AWS A20 platform consists 
basically on an electronic characterization system based on 
the fixed frequency phase-shift measurement technique 
described elsewhere [14]. F20 module is a flow-through 
automated equipment controlled by syringe pumps 
(Hamilton, Bonaduz, GR, Switzerland). This way, samples 
were delivered to the flow cell at a constant flow rate. Both 
modules were kept at 25 ºC. Both AWS A20 platform and 
F20 flow module were controlled (data acquisition and 
analysis and fluidics) by AW-BIO v1.8 dedicated software 
(AWSensors, Spain). Phase, amplitude and temperature were 
















Figure 1. A20 test platform and F20 flow module developed by 
AWSensors and used in the present study. 
2.5. Sensor functionalization. 
Sensor functionalization was carried out by means of 
covalent immobilization of the recombinant 38 kDa antigen 
on the gold electrode surface of 100 MHz HFF-QCM 
crystals. Prior to immobilization, chips were subjected to 
UV-ozone radiation for 15-20 min using a UV/Ozone 
ProCleaner from BioForceNanosciences (Ames, IA). 
Crystals were then rinsed with distilled water and ethanol 
and blown dry by a nitrogen stream. 
The covalent immobilization was carried out by means of 
classic amide chemistry. Mixed self-assembled monolayers 
(mSAM) of carboxylic alkane thiols were used as 
intermediate layers for immobilization. All procedures were 
performed on only one face of the crystal following the 
previously described protocol [30] except for the 
composition of the mSAM and the protein to be 
immobilized. The mSAM was composed by a 250 µM mixed 
solution of MHDA and MUD (1:20 molar ratio). The protein 
to be immobilized was the recombinant 38 kDa antigen. It 
was prepared at 10, 20 and 50 µg mL-1 in PBS and placed for 
4 h on previously activated crystal surfaces. 
2.6. Immunoassay format in the HFF immunosensor. 
A binding inhibition test was develop and coupled to the 
functionalized sensors in order to determine the 38 kDa 
tuberculosis biomarker with the HFF-QCM. It consisted of a 
competitive immunoassay in the antigen-coated format. To 
this purpose, a fixed amount of the selected monoclonal 
antibody (Myc-31) was mixed with standard solutions of the 
38 kDa antigen at different concentrations, and the mixtures 
were pumped over the sensor surface where the same protein 
had been previously immobilized. Since the free analyte 
(biomarker) inhibits the antibody binding to the same 
immobilized antigen, the assay signal of the piezoelectric 
sensor (phase shift) will decrease as the biomarker 
concentration increases. 
Standard 38 kDa solutions rangin from 10-3 to 102 µg L-1 
were prepared by serial dilutions in PBS and mixed with an 
equal volume of a 0.75 µg mL-1 solution of Myc-31 MAb. 
Analyte-antibody mixtures were incubated for 1 h at room 
temperature and then 650 µL of this mixture were brought 
onto the functionalized sensor surface. Variations in phase 
response were monitored in real time as the binding between 
the free antibody and the immobilized recombinant 38 kDa 
protein took place. Regeneration of the functionalized 
surfaces to break the antigen-antibody association was 
accomplished with 0.05 M HCl. 
Standards were run at least in duplicate. Calibration 
curves were obtained by plotting the phase decrease vs. 
analyte concentration. The experimental points were fitted to 
the four-parameter logistic equation described above 
(equation 3). The mean standard curve was obtained by 
averaging two individual ones, previously normalized by 
expressing the phase decrease provided by each standard 
concentration as the percentage of the maximum response 
(maximum signal,Smax= 100%) in the absence of analyte. 
2.7. Immunoassay protocol. 
The assay procedure was as follows: 
(1) Baseline stabilization: 5 min flow of working buffer 
(PBST).  
(2) Sample injection (650 µL of standard-MAb mixture) 
followed by 18 min flow of working buffer. 
(3) Regeneration (6 min) with 0.05 M HCl followed by 
working buffer (6 min).  
At steps (1) and (2) the flow rate was of 20 µL min-1. For 
step (3) it was raised to 250 µL min-1. A complete assay 
cycle, including regeneration, takes around 35 min. Once the 
last assay had finished, every day crystals were washed with 
double distilled water, air-dried and stored at 4ºC. Each 
crystal could be reused for around 35 times without 
significant loss of basal signal. 
2.8. Analytical characterization of the standard curves. 
Competitive standard curves were obtained by plotting 
the immunoassay signal (absorbance for ELISA, phase shift 
for the immunosensor) against the logarithm of the analyte 
(38 kDa biomarker) concentration. Experimental data were 
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mathematically fitted to a four-parameter logistic equation 
(equation 3):  
y = (A – D) ⁄ [1 + (x/C)B]  + D              (Eq. 3) 
Where: 
y: Immunoassay or immunosensor signal produced by 
a given analyte concentration (x). 
A: Asymptotic maximum (maximum signal, obtained in the 
absence of analyte). 
B: Curve slope at the inflection point. 
C: Analyte concentration at the inflection point, which in 
turn produces a 50% inhibition of the maximum signal (IC50 
value). 
D: Asymptotic minimum (background signal, corresponding 
to an infinite analyte concentration). 
The C parameter or IC50 value is generally assumed as an 
inverse estimate of the antibody affinity to the analyte and of 
the immunoassay or immunosensor sensitivity. Therefore, 
lower IC50 values mean higher antibody affinity and 
increased assay sensitivity, and vice versa. 
The assay limit of detection (LOD) and working range 
(WR) were also calculated from the parametric fitting of the 
standard curve. LOD was defined as the analyte 
concentration providing a 10% inhibition of the maximum 
signal (IC90 value). WR was defined by the analyte 
concentrations that produced inhibitions between 20% and 
80% of the maximum signal (IC80-IC20 range). 
3. RESULTS AND DISCUSSION 
3.1. Monoclonal antibody production. 
The application of hybridoma technology resulted in the 
production of 12 cell lines secreting MAbs that recognized 
the recombinant 38 kDa protein from Mycobacterium 
tuberculosis. All hybridomas were cloned and stabilized, and 
the affinity of their corresponding antibodies was estimated 
by non-competitive ELISA. To this purpose, microplate 
wells were coated with 0.05 µg mL-1 of the antigen and 
subsequently exposed to variable antibody concentrations. 
Myc-31 Mab provided the highest and more stable response 
against the target biomarker. Therefore, it was selected as the 
highest-affinity anti-38 kDa monoclonal antibody and used 
in further immunoassay development.  
3.2. Development of a competitive ELISA for 38 kDa 
biomarker determination. 
Checkerboard titration experiments were first conducted 
to find out the optimal concentrations of the antigen-
antibody pair for the competitive ELISA. High enough assay 
signals together with competitive conditions were provided 
by 0.05 µg mL-1 of the 38 kDa antigen for coating and 0.05 
µg mL-1 of Myc-31 MAb for the competition step. These low 
immunoreagent concentrations allowed obtaining a sensitive 
ELISA calibration curve for the target biomarker (Fig. 2). 
The ELISA standard curve was mathematically fitted 
according to equation 3 to establish its main analytical 
parameters. The calculated IC50 value was 110 ng mL
-1, the 
LOD was 14 ng mL-1 of the 38 kDa protein, and the WR was 
estimated as 30-390 ng mL-1. These low figures proved the 
high ELISA sensitivity, which made it a very useful 
analytical tool as a previous quantitative assay for 38 kDa 













Figure 2. Calibration curve of the competitive ELISA for the 38 
kDa biomarker. 
3.3. Optimization of the HFF-QCM immunoassay for 38 
kDa: Selection of immunoreagent concentrations. 
 As reported, immunosensors based on competitive 
immunoassays in the antigen-coated format, where the 
antigen is covalently immobilized  to the transducer via 
SAM or mSAM, provide the highest QCM sensor sensitivity, 
regeneration capability and reproducibility [20],[30]. As for 
most immunoassays, operating with HFF-QCM systems 
requires the previous assessment of the optimal 
concentrations of immunoreagents involved on the antigen-
antibody interaction.  
Same as for ELISA, the pair (38 kDa antigen) - (Myc-31 
MAb) was selected as the most suitable antigen-antibody 
combination to develop the HFF-QCM immunosensor. Next, 
several Myc-31 MAb concentrations ranging from 0.5 to 
50.0 µg mL-1 were assayed in sensors with 50 µg mL-1 of 
immobilized 38 kDa antigen. Once delivered to the flow cell, 
changes on phase response were measured (Δuφ) as the 
antigen-antibody interaction took place. Results are 











Figure 3. Signal variation obtained with a 100 MHz QCM sensor, 
as a function of Myc-31 MAb concentration. The sensor was 
functionalized with 50 µg mL-1 of the 38 kDa antigen. 
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Figure 4. HFF-QCM immunosensor phase response record of an antigen-free sample. The arrow indicates the injection of Myc-31 MAb. 
As expected, higher binding corresponded to increasing 
Myc-31 concentration. For this MAb, saturation was reached 
above 20 µg mL-1, nearly the same antibody concentration as 
for the only previously described HFF-QCM immunosensor  
[20]. For optimal competitive assay conditions, the selected 
MAb concentration should provide signals below 50% of the 
maximum (saturation) one. In this case, the Myc-31 MAb 
concentration that fulfills the requirements for competitive 
immunoassays should be below 2 µg mL-1. More precisely, 
the MAb concentrations which provided suitable assay 
signals (phase decreases corresponding to 100-300 mV) 
were those comprised between 0.5 and 1.0 µg mL-1. 
In order to refine the optimization process, 10, 20 and 50 
µg mL-1 of the recombinant 38 kDa protein were 
immobilized  onto 100 MHz QCM crystals and assayed in 
combination with Myc-31 MAb at concentrations comprised 
in the 0.5- 1.0 µg mL-1 range. From these experiments (data 
not shown), 20 µg mL-1 of 38 kDa antigen was selected as 
the optimal concentration for crystal functionalization, and  
0,75 µg mL-1 of Myc-31 was chosen as the optimal MAb 
concentration to ensure competitive conditions and to 
provide optimal assay signals with minimum immunoreagent 
consumption. 
3.4. HFF-QCM standard curves for 38 kDa biomarker: 
Assay sensitivity. 
Fig. 4 depicts a representative real-screen record of the 
signal obtained when an antigen-free sample was subjected 
to a FHH-QCM immunosensor assay. Only Myc-31 MAb at 
the previously selected concentration (0.75 µg mL-1) was 
present in the sample. The illustration shows the phase shift 
produced when the sensing event (binding of the antibody to 
the immobilized antigen) occurred. The interaction took 
approximately 18 min and the signal decrease was around 
200 mV, high enough for competitive immunoassays 
purposes. 
As the HFF-QCM immunosensor was working in the 
microgravimetric mode [20], measuring phase changes was 
indeed an adequate strategy to quantify the antibody-antigen 
interactions. Therefore, phase shifts were used to generate 
38kDa antigen standard curves in the immunosensor by 
assaying standard samples with different concentrations of 
the antigen in the 10-3-102 µg ml-1 range. Regeneration of the 
immnuosensor between assays was achieved by treatment 
with 0.05 M HCl. A complete assay cycle, including 
regeneration, took around 35 min. 
A representative mean HFF-QCM immunosensor 
standard curve for the 38 kDa antigen is shown in Fig. 5. It 
was obtained by averaging two individual curves with at 
least three assays for each biomarker concentration. Voltage 
phase shifts (Δuφ) were normalized by expressing them as: 
100 x Δuφ / Δuφ0,  
where Δuφ0 is the voltage phase decrease at zero analyte 
concentration (maximum signal). As for the previous 
ELISA, experimental points were fitted to the mathematical 
logistic function according to equation 3.  
 
Figure 5. Calibration curve of the HFF-QCM immunosensor for 
the 38 kDa biomarker. 
As depicted in Fig. 5 and expected for a competitive 
immunoassay, the 38 kDa standard curve obtained with the 
HFF-QCM immunosensor showed the typical sigmoidal 
shape associated to inhibition assays, where signal decreases 
as analyte concentration increases. The mathematical curve 
fitting parameters are shown in Table 1: 
Table 1: Mathematical fitting of the HFF-QCM immunosensor 
standard curve for the 38 kDa antigen. 
Parameter Mean value Std. Deviation CV (%) 
A    103.559      10.746 10.4 
B 0.913 0.089   9.7 
C 0.080 0.012 15.0 
D      12.397 2,231 18.0 
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 The parameter variability found was in the usual range 
for competitive immunoassays. Under the described 
optimized conditions, the sensitivity parameter (C = IC50 
value) was estimated as 80 ng mL-1. The LOD and WR were 
11 ng mL-1 and 20 – 450 ng mL-1 of the 38 kDa biomarker, 
respectively. These values were similar but even lower than 
those of the previously developed ELISA, which indicates 
that the immunosensor achieved a similar but even higher 
assay sensitivity and detectability than those of ELISA. In 
terms of molar units, the limit of detection of the HFF-QCM 
immunosensor was 290 pM and its working range extended 
from 530 pM to 12 nM of the 38 kDa antigen. 
 The achieved LOD clearly improves those previously 
reported for tuberculosis QCM immunosensors (up to 50 
nM) [22],[23]. To our knowledge, only a Surface Plasmon 
Resonance (SPR) immunosensor was reported to be more 
sensitive, with a LOD of 0.1 ng mL-1 [11]. Moreover, the 
analytical parameters of the HFF-QCM immunosensor are in 
the range of the antigens found in biological fluids from 
patients suffering tuberculosis [27],[28]. Therefore, this 
method could presumably allow the direct analysis of the 
biomarker in suitable patients’ samples. 
CONCLUSION 
On the basis of the thorough application of the most 
advanced immunochemical technologies (MAb production, 
ELISA and biosensor development), a high performance HFF-
QCM immunosensor was developed for the detection of the 
38 kDa tuberculosis biomarker.  
High and stable assay signals were obtained using very 
low protein concentrations for crystal functionalization and for 
the integrated competitive immunoassay. This allowed to get a 
highly sensitive immnunosensor with IC50 and LOD values 
even lower than those of the ELISA developed with the same 
immunoreagents. The high detectability attained, in the 
picomolar range, makes this immunosensor a very promising 
tool for the easy, direct and sensitive detection of the 
tuberculosis biomarker in biological fluids such as sputum. 
Current work is devoted to the validation of the HFF-
QCM immunosensor. It includes and will include the native 
antigen purification from Mycobacterium tuberculosis 
cultures and the subsequent preparation of spiked samples, 
the collection of real sputum samples from tuberculosis 
patients, the determination of the analytical performance of 
the immunosensor in both types of samples (spiked and real), 
and finally the assessment of its biomedical significance as a 
diagnosis tool. 
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